Brings over 25 years of industry and business development experience and a strong track record of executing growth and value-creating strategies to Neumora
Succeeds current chief executive officer, chairman, and co-founder Paul L. Berns who will assume the role of Executive Chairman, continuing as a key strategic leader to advance Company growth
WATERTOWN, MA, July 18, 2023 – Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Henry Gosebruch as president and chief executive officer and a member of the Company’s board. Co-founder Paul L. Berns, chief executive officer and chairman, will transition to the role of Executive Chairman and will continue to chair the board.
“I am extremely proud of the Neumora team’s unwavering commitment to patients and progress to date, which has enabled us to build a company at scale that I believe is poised to become the leader in brain health,” said Paul L. Berns, co-founder and executive chairman of Neumora. “Looking forward, I am optimistic about what’s to come given our strong business fundamentals and robust pipeline including our lead program entering Phase 3 development. This momentum allowed us to attract a leader like Henry, who is an incredibly talented biopharma executive, bringing a wealth of strategic and operating expertise. I’m pleased that he has joined the Neumora team in our mission to bring forward the next generation of novel therapies for patients suffering from CNS disorders. I have known Henry for over a decade, and I look forward to working with him and continuing to contribute to Neumora’s growth in my new role as executive chairman.”
Mr. Gosebruch is a seasoned pharmaceutical executive with extensive strategy, transaction, and operating experience. Most recently, Mr. Gosebruch served as executive vice president and chief strategy officer at AbbVie, Inc. (AbbVie), responsible for corporate strategy and long-range planning across all of AbbVie’s therapeutic franchises including neuroscience and AbbVie’s external innovation groups. In this role, Mr. Gosebruch successfully built a high performing team that contributed to AbbVie bringing a number of new medicines to patients that address areas of high unmet need.
“Neumora is at the forefront of a new era in neuroscience and is tackling one of the greatest challenges of our generation, the global brain disease crisis, by redefining neuroscience drug development with novel therapeutic programs and a precision approach,” said Henry Gosebruch, chief executive officer of Neumora. “I have been impressed with the quality of Neumora’s industry-leading pipeline of programs that may offer improved treatment outcomes and quality of life for patients suffering from brain diseases, and its differentiated approach. I look forward to working alongside the talented Neumora team realizing our founders’ vision to make a difference for people with brain disorders and become a leader in neuroscience.”
About Henry Gosebruch, Chief Executive Officer
Mr. Gosebruch served as executive vice president and chief strategy officer at AbbVie, a global biopharmaceutical company, from December 2015 to February 2023. As a member of AbbVie’s Executive Team, he created and led AbbVie’s Corporate Strategy Office, which comprised teams focused on corporate strategy and strategic planning, competitive strategy and insights, business development and M&A, search and evaluation, alliance management, R&D decision support/portfolio analytics and the company’s corporate strategic venture capital arm, AbbVie Ventures.
During his tenure at AbbVie, Mr. Gosebruch and his team oversaw the advancement of AbbVie’s partnered pipeline and assisted in making internal portfolio decisions. Mr. Gosebruch and his team were responsible for the completion of more than 100 business development/M&A transactions and venture capital investments. Notable transactions completed under Mr. Gosebruch’s tenure include AbbVie’s partnerships with Boehringer Ingelheim for risankizumab (Skyrizi) and Genmab for epcoritamab (Epkinly) that resulted in bringing new medicines to patients across several difficult-to-treat diseases with high unmet need. Mr. Gosebruch also played a pivotal role in AbbVie’s acquisition of Allergan. During his tenure, AbbVie’s annual revenues grew from approximately $23 billion to approximately $58 billion and AbbVie’s stock price and market capitalization tripled.
Prior to joining AbbVie, Mr. Gosebruch was co-head of J.P. Morgan’s North American M&A Group and worked on announced M&A transactions in excess of $375 billion in total value over a 20+ year career.
Mr. Gosebruch currently serves as a member of the board of directors of Acelyrin, Inc. where he is a member of the Audit Committee and chairs the Compensation Committee. Mr. Gosebruch is also a member of the Advisory Board for the Life Sciences & Management Program at the University of Pennsylvania. Mr. Gosebruch received a BSE in Finance from the Wharton School at the University of Pennsylvania, and is a Certified Public Accountant in Illinois.
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.
Neumora has operations in the Greater Boston Area and South San Francisco. For additional information, please visit www.neumoratx.com and follow us on Twitter: @NeumoraTx.
Investor Contact:
Helen Rubinstein
Helen.Rubinstein@neumoratx.com
Media Contact:
Katie Engleman
Katie@1abmedia.com